The Ottawa Hospital
Welcome,         Profile    Billing    Logout  
 379 Trials 
387 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goel, Rakesh
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
Laurie, Scott A
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting
2
60
Canada
Durvalumab, Prednisone, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Cancer
04/30
04/31
TWT-101, NCT04521413: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
170
Canada, US, RoW
CFI-402411, 2411, 402411, Pembrolizumab, Keytruda, pembro
Treadwell Therapeutics, Inc, TIO Discovery Engine
Advanced Solid Malignancies
11/24
12/24
NCT03990454: Safety Study of SLC-391 in Subjects With Solid Tumors

Completed
1
35
Canada
SLC-391
SignalChem Lifesciences Corporation
Solid Tumor
06/23
06/23
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
Arnold, Jennifer
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Active, not recruiting
4
446
Europe, Canada, US, RoW
Faricimab
McMaster University, Hoffmann-La Roche
Diabetic Macular Edema
12/26
12/26
PREFERRED-1, NCT05096195: PRevEnting FracturEs in REnal Disease 1

Active, not recruiting
4
60
Canada
Denosumab 60 mg/ml, Prolia, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
Western University, Canada, ICES, Academic Medical Organization of Southwestern Ontario, Western University, The Kidney Foundation of Canada
Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
12/25
12/25
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
Cheung, Angela M
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Completed
3
34
Canada
Teriparatide 20 mcg, Brand name Forteo, Placebo
University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company
Non Displaced Atypical Femoral Fractures
12/21
12/22
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
ESSOR, NCT05999435: Study of LAU-7b for the Treatment of Long COVID in Adults

Active, not recruiting
2/3
272
Canada
LAU-7b for 3 cycles, fenretinide, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles, sugar pill
Laurent Pharmaceuticals Inc.
Long COVID
08/24
10/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
NCT01155245: Teriparatide (PTH) and Bone Strength in Postmenopausal Women

Active, not recruiting
N/A
60
Canada
Forteo
University Health Network, Toronto, Eli Lilly and Company
Osteoporosis
01/24
01/25
Angel, Jonathan B
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed
2
44
Europe, Canada, US, RoW
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
Cameron, William
NCT04773665: Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Completed
1
114
Canada
VBI-2902a, Placebo, VBI-2905a
VBI Vaccines Inc.
Covid19
11/22
11/22
NCT05548439: Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a

Active, not recruiting
1
103
Canada
VBI-2901a
VBI Vaccines Inc.
COVID-19, Coronavirus Infections
02/24
02/24
NCT05614245: Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant

Withdrawn
1
60
Canada
VBI-2901e
VBI Vaccines Inc.
COVID-19, Coronavirus Infections
06/24
06/24
Patel, Rakesh
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting
3
621
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI 4920, Placebo
Amgen
Sjogren's Syndrome
08/26
08/26
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
NCT06217380: Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program

Terminated
N/A
10
Canada
Masimo SafetyNet Alert (MSNA)
Masimo Corporation
Opioid Use
02/24
02/24
JULI, NCT04726254: The Registry--Hemp and Cannabis Observational Registry

Recruiting
N/A
2000
US
Juva Life, Targeted Medical Education
Chronic Pain, Appetite Disorders, Neuropathy, Menopausal Syndrome, Anxiety, Sleep Disturbance, Nausea
02/24
02/25
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Recruiting
N/A
925
US
Blood glucose meter, Eversense CGM System
Senseonics, Inc.
Diabetes
03/26
03/26
Kim, Paul R
NCT05417074: Assessing SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Not yet recruiting
2
10
US
Placebo, SLS-002, Intranasal Racemic Ketamine, Standard of care
Johns Hopkins University, Seelos Therapeutics, Inc.
Depression, Suicidal Behavior, Suicidal Ideation
03/23
08/23
ELIMINATE, NCT05488340: A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli ( Trial)

Recruiting
2
318
US
LBP-EC01 0.1 x IV dose, 1x10^11 PFU IV dose, LBP-EC01 0.01x IV Dose, 1x10^10 PFU IV Dose, LBP-EC01 IV Infusion Dose, 1x10^12 PFU IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Locus Biosciences, Parexel
Urinary Tract Infections
06/25
12/25
NCT03543007: Evaluating the Safety and Efficacy of GrafixPL™PRIME for the Treatment of Chronic Venous Leg Ulcers

Not yet recruiting
N/A
30
US
GrafixPL™ PRIME plus standard compression therapy, standard compression therapy alone
Georgetown University, Osiris Therapeutics
Venous Leg Ulcer, Chronic Leg Ulcer, Venous Insufficiency, Venous Stasis
09/22
01/23
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
NCT04684901: Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF Procedures

Enrolling by invitation
N/A
50
US
AlloWrap® Amniotic Membrane
AlloSource
Cervical Stenosis, Spondylolisthesis, Cervical Radiculopathy, Cervical Disc Disorder
06/25
01/26
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Recruiting
N/A
250
US
The Prospera™ Test
Natera, Inc.
Heart Transplant Failure and Rejection
12/24
12/25
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

Completed
N/A
147
US
Prospera
Natera, Inc.
Heart Transplant
10/24
10/24
NCT01420237: Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study

Active, not recruiting
N/A
352
Europe, Canada, US
Restoration ADM X3 Device
Stryker Orthopaedics
Arthroplasty, Replacement, Hip
06/26
06/26
Aaron, Shawn
CanCOLD, NCT00920348: The Canadian Cohort Obstructive Lung Disease

Active, not recruiting
N/A
1500
Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Takeda, Merck Sharp & Dohme LLC, Almirall, SAS
COPD, Chronic Obstructive Pulmonary Disease
12/22
12/22
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
Vaillancourt, Christian
EpiDOSE, NCT03826524: Epinephrine Dose: Optimal Versus Standard Evaluation Trial

Recruiting
4
3790
Canada
Epinephrine, Adrenaline
Unity Health Toronto, Canadian Institutes of Health Research (CIHR), Pfizer
Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest, Ventricular Fibrillation, Ventricular Tachycardia-Pulseless
12/27
06/28
Torres, Carlos
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed
N/A
244
US
MiniMed 780G System
Medtronic Diabetes, Eli Lilly and Company
Type 1 Diabetes
01/24
01/24
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Completed
N/A
240
Canada, US, RoW
MiniMed 780G System
Medtronic Diabetes
Type 1 Diabetes
06/24
06/24
Beaule, Paul E
NCT02185365: Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia

Recruiting
N/A
25
Canada
Magnetic Resonance Imaging (MRI)
Ottawa Hospital Research Institute, Zimmer Biomet, The Ottawa Hospital Academic Medical Association
Developmental Dysplasia of the Hip
12/21
12/21
NCT02239783: Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems

Active, not recruiting
N/A
143
Canada
total hip arthroplasty implant, PROFEMUR® TL modular femoral stem
MicroPort Orthopedics Inc.
Joint Disease
11/27
11/28
NCT02149667: Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components

Active, not recruiting
N/A
48
Canada
total hip arthroplasty implant, DYNASTY® BioFoam® Acetabular Components,, DYNASTY® A-Class® Cross Linked Polyethylene Liners
MicroPort Orthopedics Inc.
Joint Disease
12/27
12/28
NCT02285842: Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components

Active, not recruiting
N/A
143
Canada
Primary hip resurfacing device
MicroPort Orthopedics Inc.
Joint Disease
12/27
12/28
Wald, Ron
PREFERRED-1, NCT05096195: PRevEnting FracturEs in REnal Disease 1

Active, not recruiting
4
60
Canada
Denosumab 60 mg/ml, Prolia, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
Western University, Canada, ICES, Academic Medical Organization of Southwestern Ontario, Western University, The Kidney Foundation of Canada
Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
12/25
12/25
Gill, John
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
VARVARA, NCT05907096: ARGX-117 in Deceased Donor Kidney Transplant Recipients At Risk for Delayed Graft Function

Recruiting
2
102
Europe, Canada, US, RoW
ARGX-117, Placebo
argenx
Delayed Graft Function
04/26
12/26
OnceDaily, NCT02426502: Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients

Active, not recruiting
N/A
76
Canada
Conversion to Advagraf, Prograf, Cyclosporine (Neoral), Advagraf, conversion of non-immunosuppressant drugs to once daily, anti-hypertensive medications, non-immunosuppressant drugs, Conversion to once daily MPA, Mycophenolate Mofetil, Myfortic, Azathioprine, Prednisone
University of British Columbia, Astellas Pharma Canada, Inc.
End-Stage Renal Disease
08/22
12/24
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
Gagnon, Bruno
CogMet, NCT02970500: Effect of Methylphenidate on Cancer-related Cognitive Impairment

Terminated
2
20
Canada
Methylphenidate HCl 10Mg SR, Placebo Group
CHU de Quebec-Universite Laval, Équipe de Recherche Michel-Sarrazin en Oncologie psychosociale et Soins palliatifs, Purdue Pharma LP, Fondation de l'Hôtel-Dieu de Lévis
Breast Cancer Female, Cancer-Related Condition
12/22
12/22
Auer, Rebecca
COV-IMMUNO, NCT04442048: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Active, not recruiting
3
195
Canada
IMM-101, Observation
Canadian Cancer Trials Group, Immodulon Therapeutics Ltd, BioCan Rx, Canadian Cancer Society (CCS), ATGen Canada Inc, Canadian Centre for Applied Research in Cancer Control (ARCC), Ontario Institute for Cancer Research
Cancer, Covid-19
05/24
12/24
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
PembroWM, NCT03630042 / 2018-001767-23: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Completed
2
17
Europe
Pembrolizumab, Rituximab
University College, London, Merck Sharp & Dohme LLC
Waldenstrom Macroglobulinemia
09/21
02/24
ZEBRA, NCT05635162: Zanubrutinib Plus Rituximab for Patients with Indolent Mantle Cell Lymphoma

Recruiting
2
50
Europe
Zanubrutinib, Rituximab
University College, London, BeiGene
Mantle Cell Lymphoma
10/28
10/28
Kilty, Shaun
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP
Completed
3
276
Europe, Canada, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nasal Polyps
07/24
08/24
NCT02975310: In-clinic Endoscopic Polypectomy for Chronic Sinusitis With Nasal Polyps

Recruiting
N/A
140
Canada
Endoscopic polypectomy in clinic (EPIC), Endoscopic Sinus Surgery (ESS), General Anesthesia, Local and topical anesthesia
Ottawa Hospital Research Institute, Canadian Institutes of Health Research (CIHR), Medtronic
Sinusitis, Nasal Polyps
12/23
12/25
Hiremath, Swapnil
PREFERRED-1, NCT05096195: PRevEnting FracturEs in REnal Disease 1

Active, not recruiting
4
60
Canada
Denosumab 60 mg/ml, Prolia, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
Western University, Canada, ICES, Academic Medical Organization of Southwestern Ontario, Western University, The Kidney Foundation of Canada
Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
12/25
12/25
Chitnis, Tanuja
NCT06292923: A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Recruiting
2
54
US
Foralumab, Placebo
Tiziana Life Sciences LTD
Secondary Progressive Multiple Sclerosis
11/24
11/24
NCT06802328: Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

Available
N/A
US
Foralumab TZLS-401 50 µg
Tiziana Life Sciences LTD
Non-Active Secondary Progressive Multiple Sclerosis
 
 
NCT05781113: A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

Recruiting
N/A
90
Europe, Canada, US
Celestra Health Systems, University of Ottawa, Barts & The London NHS Trust, The Ottawa Hospital, Brigham and Women's Hospital
Multiple Sclerosis
12/25
03/26
Wheatley-Price, Paul
OCELOT, NCT04335292: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Recruiting
2
200
Canada
Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line
Mark Vincent, AstraZeneca
Non-Small Cell Lung Cancer
06/26
06/27
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting
N/A
1000
Canada
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc.
Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation
12/25
12/25
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Waters, Kelly
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
Breau, Rodney H
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting
2
315
Canada, US
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab
University of British Columbia, Janssen Inc., University Health Network, Toronto
Prostate Cancer
04/26
04/26
Arnaout, Angel
INVINCIBLE, NCT04781725: TRIAL: Intratumoral INT230-6 in Breast Cancer

Recruiting
2
90
Canada
INT230-6, Cisplatin, Vinblastine, 2-hydroxybenzoylaminooctanoate (SAHO), Saline injection
Ottawa Hospital Research Institute, Intensity Therapeutics, Inc., Ontario Institute for Cancer Research
Breast Cancer
03/22
03/23
Nguyen, Thanh
NCT05456425: A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Recruiting
3
600
US, RoW
CBT-001, Vehicle
Cloudbreak Therapeutics, LLC
Pterygium
12/25
12/26
VOICE, NCT04648020 / 2021-000999-11: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated
2b
190
Europe, US
Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet
Monopar Therapeutics, Monopar Therapeutics Inc.
Chemoradiotherapy-Induced Severe Oral Mucositis
05/23
05/23
NCT04744662: ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Completed
1
28
RoW
ONL1204 Ophthalmic solution, sham injection
ONL Therapeutics
Geographic Atrophy
02/24
02/24
NCT05018650: A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

Active, not recruiting
N/A
250
US, RoW
Route 92 Medical Reperfusion System
Route 92 Medical, Inc.
Acute Ischemic Stroke
06/24
06/24
Awan, Arif
INVINCIBLE, NCT04781725: TRIAL: Intratumoral INT230-6 in Breast Cancer

Recruiting
2
90
Canada
INT230-6, Cisplatin, Vinblastine, 2-hydroxybenzoylaminooctanoate (SAHO), Saline injection
Ottawa Hospital Research Institute, Intensity Therapeutics, Inc., Ontario Institute for Cancer Research
Breast Cancer
03/22
03/23
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Active, not recruiting
2
142
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
12/25
09/26
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
Torres, Javier Largo
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
Delluc, Aurélien
TILE, NCT04794569: Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Terminated
4
9
Canada
tinzaparin, Rivaroxaban
Sunnybrook Health Sciences Centre, LEO Pharma, Sunnybrook Research Institute
Deep Vein Thrombosis, Post Thrombotic Syndrome
01/24
01/24
Hilton, John
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
NCT06551142: A Study of GSK5764227 in Participants With. Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Fluorouracil, Folinic acid, Cetuximab, Bevacizumab
GlaxoSmithKline
Neoplasms
07/26
03/27
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
Zuckier, Lionel S
NCT05799274: Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer

Recruiting
1
9
US
RAD301 ([68Ga]-Trivehexin)
Radiopharm Theranostics, Ltd
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
06/24
09/24
English, Shane
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
Martel, Guillaume
ADVANCE HCC, NCT05137899: Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy

Recruiting
2
70
Canada
Neoadjuvant
Ontario Clinical Oncology Group (OCOG), Hoffmann-La Roche
Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis
06/26
06/26
PRIMe, NCT04549662: The HepatoPancreaticoBiliary Resection Arginine Immunomodulation () Trial

Completed
N/A
45
Canada
Active A, Active B, Lipid bolus, Placebo oil
Sunnybrook Health Sciences Centre, Enhanced Medical Nutrition, Sunnybrook Health Sciences Centre Clinical Research Grant Competition, Sunnybrook Health Sciences Centre AFP Innovation Fund
Hepatopancreaticobiliary (HPB) Malignancy, Surgery
02/24
02/24
Castellucci, Lana
PEITHO-3, NCT04430569 / 2018-000816-96: Pulmonary Embolism International THrOmbolysis Study-3

Recruiting
3
650
Europe, Canada, RoW
Alteplase, Placebo
Assistance Publique - Hôpitaux de Paris, Johannes Gutenberg University Mainz, Life Sciences Research Partners (D Collen Research Foundation), Canadian Institutes of Health Research (CIHR), Instituto de Salud Carlos III, International Network of VENous Thromboembolism Clinical Research Networks, Boehringer Ingelheim
Pulmonary Embolism
09/25
08/27
ATTACC-CAP, NCT05848713: AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting
3
4000
Canada, US, RoW
Heparin
University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI
Community-acquired Pneumonia
03/28
03/29
Zhang, Jing
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
450
RoW
608 Q2W, 608 Q4W, Placebo, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
07/23
06/24
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
 

Download Options